Analysts Set LifeStance Health Group, Inc. (NASDAQ:LFST) Target Price at $8.63

LifeStance Health Group, Inc. (NASDAQ:LFST) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $8.50.

Several equities research analysts have issued reports on the stock. William Blair reiterated an “outperform” rating on shares of LifeStance Health Group in a research note on Friday, February 28th. The Goldman Sachs Group upgraded shares of LifeStance Health Group from a “neutral” rating to a “buy” rating and set a $10.00 target price on the stock in a report on Monday, December 16th. Finally, Canaccord Genuity Group assumed coverage on LifeStance Health Group in a report on Thursday, April 3rd. They issued a “buy” rating and a $8.00 price target for the company.

Insider Activity

In other LifeStance Health Group news, insider Lisa K. Miller sold 18,845 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $6.90, for a total transaction of $130,030.50. Following the completion of the sale, the insider now owns 339,810 shares in the company, valued at $2,344,689. This trade represents a 5.25 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 6.60% of the company’s stock.

Institutional Trading of LifeStance Health Group

Several institutional investors have recently added to or reduced their stakes in the stock. Jennison Associates LLC grew its holdings in LifeStance Health Group by 278.4% during the 4th quarter. Jennison Associates LLC now owns 8,086,380 shares of the company’s stock worth $59,597,000 after acquiring an additional 5,949,438 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of LifeStance Health Group by 87.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,524,529 shares of the company’s stock worth $25,977,000 after purchasing an additional 1,643,390 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of LifeStance Health Group by 7.9% during the fourth quarter. Vanguard Group Inc. now owns 10,689,396 shares of the company’s stock worth $78,781,000 after purchasing an additional 784,818 shares during the last quarter. Geode Capital Management LLC grew its stake in LifeStance Health Group by 26.8% in the third quarter. Geode Capital Management LLC now owns 3,452,178 shares of the company’s stock worth $24,170,000 after purchasing an additional 729,794 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in LifeStance Health Group by 15.2% in the third quarter. Wellington Management Group LLP now owns 4,830,441 shares of the company’s stock valued at $33,813,000 after buying an additional 638,385 shares during the last quarter. 85.50% of the stock is owned by institutional investors and hedge funds.

LifeStance Health Group Stock Down 2.0 %

LFST opened at $6.51 on Thursday. LifeStance Health Group has a 1 year low of $4.64 and a 1 year high of $8.61. The firm has a 50 day moving average price of $7.44 and a 200 day moving average price of $7.34. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.32 and a current ratio of 1.32. The company has a market cap of $2.50 billion, a PE ratio of -25.04 and a beta of 1.30.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.